Switch to:
Also traded in: Germany, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.53
NVAX's Cash-to-Debt is ranked lower than
88% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. NVAX: 0.53 )
Ranked among companies with meaningful Cash-to-Debt only.
NVAX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 5.25 Max: No Debt
Current: 0.53
0.07
No Debt
Equity-to-Asset -0.31
NVAX's Equity-to-Asset is ranked lower than
96% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. NVAX: -0.31 )
Ranked among companies with meaningful Equity-to-Asset only.
NVAX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.36  Med: 0.76 Max: 0.98
Current: -0.31
-0.36
0.98
Debt-to-Equity -3.63
NVAX's Debt-to-Equity is ranked lower than
99.99% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. NVAX: -3.63 )
Ranked among companies with meaningful Debt-to-Equity only.
NVAX' s Debt-to-Equity Range Over the Past 10 Years
Min: -57.04  Med: 0.1 Max: 6.35
Current: -3.63
-57.04
6.35
Debt-to-EBITDA -1.96
NVAX's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. NVAX: -1.96 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NVAX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.99  Med: -0.03 Max: 0
Current: -1.96
-1.99
0
Piotroski F-Score: 2
Altman Z-Score: -5.96
Beneish M-Score: -1.71
WACC vs ROIC
17.66%
-258.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -446.33
NVAX's Operating Margin % is ranked lower than
68% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. NVAX: -446.33 )
Ranked among companies with meaningful Operating Margin % only.
NVAX' s Operating Margin % Range Over the Past 10 Years
Min: -11502.46  Med: -492.27 Max: -134.38
Current: -446.33
-11502.46
-134.38
Net Margin % -475.36
NVAX's Net Margin % is ranked lower than
70% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. NVAX: -475.36 )
Ranked among companies with meaningful Net Margin % only.
NVAX' s Net Margin % Range Over the Past 10 Years
Min: -12414.15  Med: -511.2 Max: -129.13
Current: -475.36
-12414.15
-129.13
ROA % -59.93
NVAX's ROA % is ranked lower than
68% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. NVAX: -59.93 )
Ranked among companies with meaningful ROA % only.
NVAX' s ROA % Range Over the Past 10 Years
Min: -71.75  Med: -43.73 Max: -27.39
Current: -59.93
-71.75
-27.39
ROC (Joel Greenblatt) % -492.51
NVAX's ROC (Joel Greenblatt) % is ranked higher than
52% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. NVAX: -492.51 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NVAX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -736.29  Med: -469.42 Max: -251.52
Current: -492.51
-736.29
-251.52
3-Year Revenue Growth Rate -7.70
NVAX's 3-Year Revenue Growth Rate is ranked lower than
61% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NVAX: -7.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NVAX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -57.7  Med: -6.3 Max: 247.6
Current: -7.7
-57.7
247.6
3-Year EBITDA Growth Rate -16.30
NVAX's 3-Year EBITDA Growth Rate is ranked lower than
72% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. NVAX: -16.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NVAX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -102.6  Med: 4.4 Max: 58.7
Current: -16.3
-102.6
58.7
3-Year EPS without NRI Growth Rate -19.40
NVAX's 3-Year EPS without NRI Growth Rate is ranked lower than
75% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. NVAX: -19.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NVAX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -12.5 Max: 45.6
Current: -19.4
0
45.6
GuruFocus has detected 4 Warning Signs with Novavax Inc NVAX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NVAX's 30-Y Financials

Financials (Next Earnings Date: 2018-11-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

NVAX Guru Trades in Q3 2017

Jim Simons 2,709,954 sh (+117.46%)
Chuck Royce 550,000 sh (unchged)
» More
Q4 2017

NVAX Guru Trades in Q4 2017

Ken Fisher 143,965 sh (New)
Jim Simons 2,815,565 sh (+3.90%)
Chuck Royce 550,000 sh (unchged)
» More
Q1 2018

NVAX Guru Trades in Q1 2018

Jim Simons 5,786,464 sh (+105.52%)
Ken Fisher 143,965 sh (unchged)
Chuck Royce 390,000 sh (-29.09%)
» More
Q2 2018

NVAX Guru Trades in Q2 2018

Paul Tudor Jones 17,381 sh (New)
Ken Fisher 143,965 sh (unchged)
Jim Simons Sold Out
Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:NVAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-12-31 New Buy$1 - $1.54 $ 1.8955%143,965
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:GERN, NAS:VYGR, SZSE:300653, NAS:ACIU, NAS:FATE, XPAR:STAGR, NAS:ODT, NAS:FPRX, NAS:AKAO, NAS:DRNA, XKRX:031390, NAS:CDXS, NAS:CASI, ROCO:4157, NAS:ARWR, NAS:CMTA, NAS:SRNE, NAS:RYTM, LSE:PRTC, SZSE:002898 » details
Traded in other countries:NVV.Germany, 0UP6.UK,
Headquarter Location:USA
Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.

Novavax is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Ratios

vs
industry
vs
history
PS Ratio 15.88
NVAX's PS Ratio is ranked lower than
52% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVAX: 15.88 )
Ranked among companies with meaningful PS Ratio only.
NVAX' s PS Ratio Range Over the Past 10 Years
Min: 6.47  Med: 42.72 Max: 1903.33
Current: 15.88
6.47
1903.33
EV-to-EBIT -5.07
NVAX's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. NVAX: -5.07 )
Ranked among companies with meaningful EV-to-EBIT only.
NVAX' s EV-to-EBIT Range Over the Past 10 Years
Min: -33.8  Med: -6.7 Max: -1
Current: -5.07
-33.8
-1
EV-to-EBITDA -5.38
NVAX's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. NVAX: -5.38 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVAX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -35.8  Med: -7 Max: -1.1
Current: -5.38
-35.8
-1.1
EV-to-Revenue 22.31
NVAX's EV-to-Revenue is ranked lower than
58% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. NVAX: 22.31 )
Ranked among companies with meaningful EV-to-Revenue only.
NVAX' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.8  Med: 40.75 Max: 1536.9
Current: 22.31
5.8
1536.9
Current Ratio 4.52
NVAX's Current Ratio is ranked lower than
54% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. NVAX: 4.52 )
Ranked among companies with meaningful Current Ratio only.
NVAX' s Current Ratio Range Over the Past 10 Years
Min: 0.44  Med: 4.43 Max: 37
Current: 4.52
0.44
37
Quick Ratio 4.52
NVAX's Quick Ratio is ranked lower than
51% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. NVAX: 4.52 )
Ranked among companies with meaningful Quick Ratio only.
NVAX' s Quick Ratio Range Over the Past 10 Years
Min: 0.44  Med: 4.37 Max: 37
Current: 4.52
0.44
37

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.60
NVAX's 3-Year Average Share Buyback Ratio is ranked higher than
58% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. NVAX: -10.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -29.9  Med: -19.2 Max: -8.1
Current: -10.6
-29.9
-8.1

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.37
NVAX's Price-to-Median-PS-Value is ranked higher than
89% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. NVAX: 0.37 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NVAX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.1  Med: 1.02 Max: 30.46
Current: 0.37
0.1
30.46
Earnings Yield (Greenblatt) % -19.72
NVAX's Earnings Yield (Greenblatt) % is ranked lower than
75% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. NVAX: -19.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NVAX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -96.2  Med: -15 Max: -3
Current: -19.72
-96.2
-3

More Statistics

Revenue (TTM) (Mil) $39.19
EPS (TTM) $ -0.57
Beta3.38
Volatility82.22%
52-Week Range $0.96 - 2.75
Shares Outstanding (Mil)382.59

Analyst Estimate

Dec18 Dec19
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.76 -0.54
EPS without NRI ($) -0.76 -0.54
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}